

Date: 25th April, 2022

To,
National Stock Exchange of India Limited

Exchange Plaza
BandraKurla Complex
Bandra (E), Mumbai – 400051
Scrip Code: MARKSANS

To, BSE Limited P. J. Towers Dalal Street Mumbai – 400 001 Scrip Code: 524404

Sub: Intimation under Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Acquisition of Access Healthcare for Medical Products L.L.C.

Further to our letter of even date and pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, kindly be informed that the Company has signed agreement for acquiring 100% share capital of Access Healthcare for Medical Products LLC based in Dubai. Enclosed herewith please find details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/ 4/2015 dated September 9, 2015 given in Annexure A to this letter.

Kindly take the above intimation on your record.

For Marksans Pharma Limited

Harshavardhan Panigrahi Company Secretary

CIN: L24110MH1992PLC066364

www.marksanspharma.com

Annexure A
Acquisition (including agreement to acquire)

Sr. No.	Details of Events that need to be provided	Information of such events(s)
1	Name of the target entity, details in brief such as size, turnover etc.	Access Healthcare for Medical Products L.L.C is a Foreign Company incorporated on 12 th May, 2019 having registered office at Al Wasl, Bur Dubai, Dubai, United Arab Emirates with an annual turnover of AED 12 Mn and net-worth of AED 1.53 Mn as on June 30, 2021.
2	Whether the acquisition would fall within related party transaction(s)and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof	The transaction is between the Company and the shareholders of Access Healthcare for Medical Products L.L.C, who are not a related party to the Company, the transaction will not fall within related party transaction(s) for the Company.
	and whether the same is done at "arms length"	
3	Industry to which the entity being acquired belongs	Access Healthcare for Medical Products L.L.C is engaged in the business of marketing of medicines in the United Arab Emirates and neighboring countries.
4	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	This acquisition will enable Marksans to use the front-end sales and marketing infrastructure of Access Healthcare for marketing its products manufactured in the India, UK, and USA regions. It will bolster Marksans' presence in the Middle East and North African regions by leveraging Access Health's knowledge of local business cultures and access to a network of partners and distributors in those regions.
5	Brief details of any governmental or regulatory approvals required for the acquisition	No approval will require for the acquisition.
6	Indicative time period for completion of the acquisition	The acquisition is expected to be completed by 30.06.2022.
7	Nature of consideration -whether cash consideration or share swap and details of the same	Cash consideration
8	Cost of acquisition or the price at which the shares are acquired	The Company will acquire entire shareholding of Access Healthcare for Medical Products L.L.C for a total consideration of AED 13,000,000
9	Percentage of shareholding / control acquired and / or number of shares acquired	The Company will acquire 100% share capital of Access Healthcare for Medical Products L.L.C
10	Brief background about the entity acquired in terms of products/line of business	Access Healthcare for Medical Products (Access Healthcare) provides pharmaceutical companies



acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)

innovative marketing and sales solutions in the MENA (Middle East & North Africa) region. The Company supplies these products in the UAE and other neighboring countries. In the UAE market, the company supplies products through the Dubai Health Authority (DHA). It has market authorizations by the UAE regulatory authorities for various products. For the year ended December 2021, Access Healthcare for Medical Products posted revenues of AED 12 Mn (INR 250 Mn) and a profit after tax of AED 4.5 Mn (INR 94 Mn). The company has no debt on its books.

